CA2623024C - Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives - Google Patents

Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives Download PDF

Info

Publication number
CA2623024C
CA2623024C CA2623024A CA2623024A CA2623024C CA 2623024 C CA2623024 C CA 2623024C CA 2623024 A CA2623024 A CA 2623024A CA 2623024 A CA2623024 A CA 2623024A CA 2623024 C CA2623024 C CA 2623024C
Authority
CA
Canada
Prior art keywords
daily doses
stage
dienogest
combination
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2623024A
Other languages
English (en)
French (fr)
Other versions
CA2623024A1 (en
Inventor
Susan Zeun
Pol Boudes
Jan Endrikat
Angelo Secci
Holger Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35811580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2623024(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CA2623024A1 publication Critical patent/CA2623024A1/en
Application granted granted Critical
Publication of CA2623024C publication Critical patent/CA2623024C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA2623024A 2005-10-13 2006-10-12 Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives Active CA2623024C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05022324A EP1787649B1 (de) 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
EP05022324.7 2005-10-13
PCT/EP2006/009867 WO2007042296A1 (de) 2005-10-13 2006-10-12 Verwendung von estradiolvalerat oder estradiol in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption

Publications (2)

Publication Number Publication Date
CA2623024A1 CA2623024A1 (en) 2007-04-19
CA2623024C true CA2623024C (en) 2012-03-06

Family

ID=35811580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2623024A Active CA2623024C (en) 2005-10-13 2006-10-12 Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives

Country Status (22)

Country Link
EP (2) EP1787649B1 (https=)
JP (2) JP5735200B2 (https=)
KR (2) KR101218872B1 (https=)
CN (1) CN101312733A (https=)
AR (1) AR056694A1 (https=)
AT (2) ATE424828T1 (https=)
CA (1) CA2623024C (https=)
CL (1) CL2011000283A1 (https=)
CY (2) CY1110321T1 (https=)
DE (2) DE502005006837D1 (https=)
DK (2) DK1787649T3 (https=)
DO (1) DOP2006000221A (https=)
ES (2) ES2322479T3 (https=)
HR (1) HRP20090256T1 (https=)
ME (1) ME01056B (https=)
PE (2) PE20100090A1 (https=)
PL (2) PL1787649T3 (https=)
PT (2) PT1787649E (https=)
SI (2) SI1787649T1 (https=)
TW (2) TWI328453B (https=)
UY (1) UY29861A1 (https=)
WO (1) WO2007042296A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
ATE249222T1 (de) * 1996-07-26 2003-09-15 Wyeth Corp Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
EP1462106A1 (en) * 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo

Also Published As

Publication number Publication date
CA2623024A1 (en) 2007-04-19
EP1933843A1 (de) 2008-06-25
ES2322479T3 (es) 2009-06-22
WO2007042296A1 (de) 2007-04-19
ATE424828T1 (de) 2009-03-15
JP5735200B2 (ja) 2015-06-17
JP2009511526A (ja) 2009-03-19
SI1933843T1 (sl) 2011-06-30
PT1787649E (pt) 2009-05-08
EP1787649A1 (de) 2007-05-23
ES2360302T3 (es) 2011-06-02
CL2011000283A1 (es) 2011-07-08
PT1933843E (pt) 2011-04-29
KR20080065651A (ko) 2008-07-14
HRP20090256T1 (en) 2009-06-30
AR056694A1 (es) 2007-10-17
DE502005006837D1 (de) 2009-04-23
PL1933843T3 (pl) 2011-06-30
SI1787649T1 (sl) 2009-08-31
TW200731977A (en) 2007-09-01
DOP2006000221A (es) 2007-08-31
PE20100090A1 (es) 2010-03-12
CN101312733A (zh) 2008-11-26
DK1787649T3 (da) 2009-06-02
TWI328453B (en) 2010-08-11
UY29861A1 (es) 2007-05-31
DE502006008853D1 (de) 2011-03-17
EP1787649B1 (de) 2009-03-11
TW200829255A (en) 2008-07-16
ATE497387T1 (de) 2011-02-15
CY1111406T1 (el) 2015-08-05
KR20100082389A (ko) 2010-07-16
PL1787649T3 (pl) 2009-08-31
KR101218872B1 (ko) 2013-01-07
CY1110321T1 (el) 2015-01-14
DK1933843T3 (da) 2011-04-18
PE20070555A1 (es) 2007-07-12
JP2013047269A (ja) 2013-03-07
ME01056B (me) 2012-10-20
EP1933843B1 (de) 2011-02-02

Similar Documents

Publication Publication Date Title
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
AU716249B2 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
FI117850B (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
HU223753B1 (hu) Természetes ösztrogén bázisú többlépcsős fogamzásgátló készítmény
JP2007512291A (ja) ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤
JPH09502194A (ja) 少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤
AU726091B2 (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
CZ20012184A3 (cs) Třífázová perorální antikoncepce
ZA200404249B (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU759925B2 (en) Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin
JP2000515888A (ja) 経口避妊薬
JP2013047269A (ja) 経口避妊薬の形での機能不全子宮出血の経口治療のためへの吉草酸エストラジオール又はエストラジオールとジエノゲストとの使用
CN1186023C (zh) 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
US20100190757A1 (en) Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
RU2000115313A (ru) Схемы приема гестаген-анти-гестагена
Tantbirojn et al. Clinical comparative study of oral contraceptives containing 30 μg ethinylestradiol/150 μg levonorgestrel, and 35 μg ethinylestradiol/250 μg norgestimate in Thai women
Affinito et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol
US20060183725A1 (en) Pharmaceutical preparation for oral contraception
HK1124267A (en) Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
US20070088011A1 (en) Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20070088010A1 (en) Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
ES2382459T3 (es) Utilización de valerato de estradiol, en combinación con dienogest para la terapia por vía oral de la hemorragia uterina disfuncional, en unión con una contracepción oral
Edelman et al. An assessment of the side effects of switching from one oral contraceptive to another
CA2590004A1 (en) Contraceptive pharmaceutical preparation
CA2624380A1 (en) Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916